HomeProductsBioactive CompoundsAnti-Infective AgentsHIV ProteaseDoravirine
Chemical structure of CAS 1338225-97-0

Doravirine

CAS No.1338225-97-0
MDL No.MFCD22417167
MFC17H11ClF3N5O3
MW425.70
InChI KeyZIAOVIPSKUPPQW-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1338225-97-0
Product NameDoravirine

Associated Conditions

kidney disease·viral disease·HIV infection·HIV-1 infection
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.

Xenobiotica; the fate of foreign compounds in biological systems • Vol. 49, Issue 4 • 2019
PMID: 29557716DOI: 10.1080/00498254.2018.1451667

Clinical Pharmacokinetics and Drug Interactions of Doravirine.

European journal of drug metabolism and pharmacokinetics • Vol. 43, Issue 6 • 2018
PMID: 30047107DOI: 10.1007/s13318-018-0497-3

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Antimicrobial agents and chemotherapy • Vol. 58, Issue 3 • 2014
PMID: 24379202PMC: PMC3957832DOI: 10.1128/AAC.02403-13

HIV-1 reverse transcription.

Cold Spring Harbor perspectives in medicine • Vol. 2, Issue 10 • 2012
PMID: 23028129PMC: PMC3475395DOI: 10.1101/cshperspect.a006882

Documentation

Similar Products